Company Information
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. The company concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, the company has recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. The company's headquartered in Seattle, Washington.
| Organization | CTI BioPharma Corp |
| Employees | 23 |
| CEO | Adam Craig |
| Industry | Health Technology |
Company Financials
Institutional Holdings
Bvf Inc
8.19%
NEA Management Company, LLC
6.55%
Lion Point Capital, LP
5.04%
Stonepine Capital Management Llc
4.3%
Bleichroeder LP
3.54%
Vanguard Group Inc
3.3%
